H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Lipocine (LPCN) today and set a price target of $5. The company’s shares closed yesterday at $1.93.
Livnat noted:
“Valuation and risk. Our $5 target includes $3/share DCF value for Tlando oral TRT for hypogonadism, plus a $2/share value for the LPCN-1144 NASH opportunity. Our Tlando DCF still reflects just a 30% probability of success, 13% WACC discount rate and 2% terminal growth beyond 2024. Our model reflects late-2019 Tlando approval, a commercial partnership, 2020 launch, and peak partner sales over $300M generating over $75M annual royalty revenue to Lipocine.”
According to TipRanks.com, Livnat is a 4-star analyst with an average return of 10.6% and a 49.2% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals Inc, Taiwan Liposome Company Ltd, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lipocine with a $5 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.64 and a one-year low of $1.04. Currently, Lipocine has an average volume of 340.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lipocine, Inc. operates as a pharmaceutical company, which engages in the research and development of treatment for use in men’s and women’s health through proprietary drug delivery technologies. It focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded in 2011 and is headquartered in Salt Lake City, UT.
